|Tel||+44 (0)1865 289422|
Helen Dakin joined the Health Economics Research Centre in February 2008. Before starting at HERC, she worked at Abacus International and completed her MSc in Economic Evaluation in Healthcare at City University. She previously graduated from Cambridge University with Masters and Bachelor's degrees in Biochemistry. In 2014, she completed a DPhil at the University of Oxford on the optimal methods for conducting economic evaluations of factorial clinical trials.
Her current projects include: the STAR trial, which evaluates radiotherapy alongside bevacizumab (Avastin) in age-related macular degeneration; the ACHE study, which evaluates clinical tools and thresholds for selecting patients for joint replacement; and the KAT trial, which assesses the cost-effectiveness of different types of knee replacement component.
Research paper on factors influencing NICE decisions available here.
Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.
Dakin H. and Gray A., (2017), Stat Med, 36, 2814 - 2830
Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial.
Violato M. et al, (2016), BMJ Open, 6
The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial.
Reeves BC. et al, (2016), Health Technol Assess, 20, 1 - 120
Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L.
Dixon P. et al, (2016), Qual Life Res, 25, 935 - 945
Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement.
Petrou S. et al, (2016), Qual Life Res, 25, 275 - 281